In this issue:
- SVS responds to New York Times exposé on overuse of vascular interventions
- Long-awaited FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
- Vascular surgery added as named specialty to influential national hospital rankings
- Guest Editorial: Adam Tanious, MD, ruminates on how to navigate industry rep exchanges
- uTBAD: A new randomized trial aimed at improving the lives of aortic dissection patients
